Studies have shown that one of the causes of cataract formation is that soluble proteins in the lens are gradually transformed into insoluble proteins by the action of quinones. Quinones are formed by the abnormal metabolism of tryptophan, an important functional amino acid in the body. The effect of such quinones on soluble proteins in the lens can be competitively inhibited by pyrenoxetine sodium. In addition, pyrenoxetine sodium can also fight against cataracts caused by free radical damage to the lens. Therefore, this product has a certain inhibitory effect on the development of cataracts. Animal experiments have shown that pyrenoxetine sodium can reduce the incidence of posterior capsule opacity after extracapsular cataract extraction.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

It has antifungal effect and can also have bactericidal effect at high concentrations. It mainly interferes with the activity of cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol, the main steroid in the fungal cell membrane, damaging the fungal cell membrane and changing its permeability, resulting in leakage of important intracellular substances; it can also inhibit the biosynthesis of triglycerides and phospholipids of fungi, inhibit the activity of oxidases and peroxidases, cause the accumulation of hydrogen peroxide in cells, and lead to deformation of cell submicrostructures and cell necrosis. For Candida albicans, it can inhibit the process of its transformation from spores to invasive hyphae. It is sensitive to Candida, Cryptococcus, Coccidioides, Histoplasma, etc.

A broad-spectrum quinolone antibacterial agent. It has strong bactericidal activity against Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. In vivo antibacterial efficacy tests in animal infection models show that this product is superior to norfloxacin and enoxacin.